Lumos Pharma (LUMO) Q3 2024 earnings summary

Executive summary

• Entered definitive merger agreement for acquisition by Double Point Ventures LLC at $4.25/share plus contingent value rights (CVRs); transaction expected to close by year-end 2024, subject to conditions.

• LUM-201 Phase 2 trials met all endpoints; FDA alignment reached on Phase 3 design, with trial initiation targeted for Q2 2025 pending merger completion.

• Company remains focused on LUM-201 for pediatric growth hormone deficiency (PGHD) and exploring additional indications as resources allow.

Financial highlights

• Q3 2024 royalty revenue was $0.7M, up from $7K in Q3 2023, driven by ERVEBO® vaccine sales; nine-month royalty revenue was $1.4M, up 13% year-over-year.

• Q3 2024 net loss was $7.5M ($0.90/share), improved from $8.3M ($1.04/share) in Q3 2023; nine-month net loss was $25.5M ($3.11/share), compared to $24.6M ($3.01/share) in 2023.

• Operating expenses for Q3 2024 were $8.4M, down 6% year-over-year; R&D expenses decreased 18% to $4.2M, while G&A increased 8% to $4.2M.

• Cash and equivalents at September 30, 2024 were $13.5M, down from $35.1M at year-end 2023; accumulated deficit reached $187.0M.

Outlook and guidance

• Substantial doubt exists about ability to continue as a going concern; current cash is insufficient to fund operations for 12 months from filing date.

• If the merger does not close, company will need to secure additional capital or may be forced to further delay, reduce, or cease operations.

• Phase 3 LUM-201 trial initiation is contingent on closing of the merger and securing necessary funding.